Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1383922 | 0.95 | SCD (0.77) | SCDDCTPP1 | |
| SCHEMBL1386336 | 0.94 | SCD (0.69) | SCDDCTPP1 | |
| SCHEMBL1600619 | 0.89 | SCD (0.68) | SCDDCTPP1 | |
| SCHEMBL1385398 | 0.88 | SCD (0.60) | SCDDCTPP1 | |
| SCHEMBL3673233 | 0.87 | SCD (1.00) | SCDDCTPP1 | |
| SCHEMBL1601540 | 0.87 | SCD (1.00) | SCDDCTPP1 | |
| SCHEMBL1385471 | 0.86 | SCD (0.78) | SCDDCTPP1 | |
| SCHEMBL1384433 | 0.86 | SCD (0.76) | SCDDCTPP1 | |
| SCHEMBL937531 | 0.86 | SCD (1.00) | SCDDCTPP1 | |
| SCHEMBL2464830 | 0.85 | SCD (0.69) | SCDDCTPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4838128-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-1651620-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-11-09 | — | — | EP | claimed |
| EP-1846035-B1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC (CA) | 2011-09-21 | — | — | EP | claimed |
| US-20090131447-A1 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2009-05-21 | — | — | US | claimed |
| US-7456180-B2 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2008-11-25 | — | — | US | claimed |
| JP-2007500720-A | — | — | 2007-01-18 | — | — | JP | claimed |
| US-20060252767-A1 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | claimed |
| EP-1651620-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | claimed |
| WO-2005011657-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| EP-1651620-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-11-09 | — | — | EP | disclosed |
| EP-1651620-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-11-09 | — | — | EP | disclosed |
| US-8030488-B2 | Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2011-10-04 | — | — | US | disclosed |
| US-8030488-B2 | Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2011-10-04 | — | — | US | disclosed |
| US-8030488-B2 | Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2011-10-04 | — | — | US | disclosed |
| EP-1846035-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2007-10-24 | — | — | EP | disclosed |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-19 | — | — | US | disclosed |
| US-20060252767-A1 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | disclosed |
| EP-1651620-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005011657-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252767-A1 | Piperazine derivatives and their use as therapeutic agents | ARG2, S1PR5, S1PR1 | SCD 17/4885DCTPP1 2358/4885 |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | APP, BACE1, PSEN1 | SCD 1186/4885DCTPP1 4175/4885 |
| US-20090131447-A1 | COMBINATION THERAPY | SCD, SCD5, ARG1 | SCD 1/4885DCTPP1 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.